Monday , November 20 2017
Home / Therapies / SGLT-2 Therapy Center (page 16)

SGLT-2 Therapy Center

Diabetes in Control is pleased to provide you with the latest insights and information on the Sodium-Dependent Glucose Transporter Two (SGLT-2) drug class to help optimize your practice. We hope you’ll benefit from the insights and share them with your colleagues. Thanks for all you’re doing to improve your patients’ lives and longevity!

ADA 2014 UPDATE: SGLT2-Inhibitors

There was a lot of great information at this year’s ADA Scientific Sessions on the sodium glucose co-transporter 2 (SGLT2) inhibitors both alone and in combination with other medications, and we have a review for you. Canagliflozin  Canagliflozin has demonstrated improvement in glycemic control, body weight, and blood pressure across …

Read More »

Surprising Trends in the Use of Antidiabetic Drugs

Researchers track data on antidiabetic prescriptions dispensed from retail pharmacies in the US and note some interesting prescribing patterns. What is the most antidiabetic drug dispensed?… See more SGLT-2 Resources Despite the ability of nonpharmacological methods such as lifestyle interventions and bariatric surgery to improve type 2 diabetes outcomes, most …

Read More »

John Anderson, MD, Q3: What is the ADA doing about prevention of diabetes and prediabetes?

John-Anderson

John Anderson, MD, talks about the efforts of the American Diabetes Association, and how they are using the successful experiences they have gained through landmark studies such as the Diabetes Prevention Program (DPP), applying this knowledge to new initiatives such as outreach into the community through the YMCA and other …

Read More »